[Federal Register Volume 89, Number 170 (Tuesday, September 3, 2024)]
[Notices]
[Pages 71276-71277]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19623]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2024-0063]
Meeting of the Advisory Committee to the Director (ACD), Centers
for Disease Control and Prevention
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting for the Advisory Committee to the Director, Centers
for Disease Control and Prevention (ACD, CDC). This is a hybrid
meeting, accessible both in person and virtually (webcast live via the
World Wide Web). It is open to the public and limited only by the space
available.
DATES: The meeting will be held on October 22, 2024, from 9 a.m. to
3:30 p.m., EDT (times subject to change).
The public may submit written comments from September 3, 2024
through October 7, 2024.
ADDRESSES: Meeting address: CDC Roybal Campus, Building 19, Auditorium
B3, 1600 Clifton Road NE, Atlanta, Georgia 30329-4027.
Please note that the meeting location, the CDC Roybal Campus, is a
federal facility and in-person access is limited to United States
citizens unless prior authorizations, taking up to 30 to 60 days, have
been made.
Registration: You must register to attend this meeting in person.
If you wish to attend in person, please submit a request by email to
[email protected] at least 5 business days in advance of the meeting.
No registration is required to view the meeting via the World Wide Web.
Information for accessing the webcast will be available at https://www.cdc.gov/about/advisory-committee-director/.
Written comments: You may submit comments, identified by Docket No.
CDC-2024-0063 by either of the following methods below. Do not submit
comments for the docket by email. CDC does not accept comments for the
docket by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Demetria Gardner, BA, Centers for Disease Control
and Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia
30329-4027. Attn: Docket number CDC-2024-0063.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov, suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted up to 72 hours prior to the ACD
meeting will be provided to ACD members before the meeting. Written
comments received in advance of the meeting will be included in the
official record of the meeting.
FOR FURTHER INFORMATION CONTACT: Demetria Gardner, BA, Office of the
Chief of Staff, Centers for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027,
Telephone: (770) 488-4745; Email Address: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to the Director, CDC, shall (1)
make recommendations to the Director regarding ways to prioritize the
activities of the agency in alignment with the CDC Strategic Plan
required under section 305(c); H.R. 2617-1252; (2) advise on ways to
achieve or improve performance metrics in relation to the CDC Strategic
Plan, and other relevant metrics, as appropriate; (3)
[[Page 71277]]
provide advice and recommendations on the development of the Strategic
Plan, and any subsequent updates, as appropriate; (4) advise on grant,
cooperative agreements, contracts, or other transactions, as
applicable; (5) provide other advice to the Director, as requested, to
fulfill duties under sections 301 and 311; and (6) appoint
subcommittees. The committee recommends ways to prioritize CDC's
activities, improve results, and address health disparities. It also
provides guidance to help CDC work more effectively with its various
private and public sector constituents to make health protection a
practical reality.
Matters to be Considered: The agenda will include an update on
priorities from the CDC Director, discussions on strategic science and
impact, artificial intelligence, childhood immunization coverage and
efforts to address lagging rates, global update, and updates from the
ACD Data and Surveillance Workgroup and the Communications and Public
Engagement Workgroup. Agenda items are subject to change as priorities
dictate.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on September 3, 2024 through October 7, 2024.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-19623 Filed 8-30-24; 8:45 am]
BILLING CODE 4163-18-P